IBRX Stock’s Decline Makes Retail See ‘Incredible’ Buying Opportunity After Anktiva + BCG Therapy Delivered Favorable Results

• The data was presented at the 2026 American Urological Association Annual Meeting.
• Anktiva plus BCG showed a longer median duration of complete response of 22.1 months, compared with 9.7 months with Nadofaragene.
• Patients treated with Anktiva plus BCG experienced far fewer treatment-related side effects compared with TAR-200.

Shares of ImmunityBio (IBRX) returned to the spotlight after the biotech company unveiled promising new data at the 2026 American Urological Association Annual Meeting, showing that its Anktiva plus Bacillus Calmette–Guérin immunotherapy delivered favorable results compared with competing bladder cancer treatments.

IBRX’s Immunotherapy Sees Higher Response Rates

Anktiva plus BCG delivered higher complete response rates and longer-lasting benefits than FDA-approved bladder cancer treatments, Ferring Pharmaceuticals’ Nadofaragene Firadenovec, marketed as Adstiladrin, and Johnson & Johnson’s TAR-200, in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

Patients treated with Anktiva plus BCG had a significantly longer median duration of complete response of 22.1 months, compared with 9.7 months with Nadofaragene.

In a separate comparison with TAR-200, ImmunityBio’s therapy showed a slightly higher 12-month complete response rate, though the difference was not statistically significant. However, patients treated with Anktiva plus BCG experienced far fewer treatment-related side effects, with a 68% lower risk of adverse events than those treated with TAR-200.

The findings were presented in two analyses at AUA 2026 using indirect treatment-comparison methods, as no head-to-head clinical trials have been conducted to date.

IBRX’s Patent Wins

On Monday, ImmunityBio secured five U.S. patents covering the use of Anktiva in combination with BCG, with protection lasting through 2035.

The new patents also support the company’s recently announced exclusive U.S. development and supply agreement with Japan BCG Laboratory. The deal gives ImmunityBio a second potential supply source for bladder cancer treatment.

Retail’s Take On IBRX

Retail sentiment on Stocktwits remained ‘bullish’ over the past 24 hours, amid ‘high’ message volumes.

One user said the stock being available for less than $8 is “incredible” given all the data being released.

Another user called the latest data “game-changing for bladder preservation.”

IBRX shares were trading 7% lower at the time of writing. The stock has gained over 250% so far this year.

Read also: CODX Stock Nearly Doubled In Early Trade – Co-Diagnostics’ Ebola Strategy Gets Retail Betting Big

For updates and corrections, email newsroom[at]stocktwits[dot]com.